No Data
No Data
Pioneer Pharmaceutical Biotechnology (00399.HK): The placement agreement has expired
Gelonghui, April 19 | Pilot Pharmaceutical Biotechnology (00399.HK) announced that since the prerequisites contained in the placement agreement were not fully reached or satisfied before April 18, 2024, the placement agreement has expired and the placement matters will not proceed.
Pilot Pharmaceutical Biotechnology (00399) plans to discount approximately 12.5% of up to 114 million shares to raise a net of HK$18.204 million
According to Zhitong Finance App, Pilot Pharmaceutical Biotechnology (00399) announced that on March 28, 2024, the company entered into a placement agreement with the placement agent. The placement agent has agreed to act as the company's agent to wholeheartedly induce no less than six undertakers (whose ultimate beneficial owner should be an independent third party) to subscribe for up to 114 million shares at an placement price of HK$0.175 per share. Assuming that the company's issued share capital will not change from the date of this announcement to the date of completion of the placement, the maximum number of placed shares of 114 million placed shares will account for the company that has been expanded through the allocation and issuance of all placed shares
Pilot Pharmaceutical Biotechnology (00399) issued 55 million shares due to the exercise of the right to convert convertible bonds
Pilot Pharmaceutical Biotechnology (00399) issued an announcement according to the exercise of convertible shares issued on April 30, 2015...
Pilot Pharmaceutical Biotechnology (00399.HK) received an additional 50 million shares of common stock worth approximately HK$10.5 million from Chow Yiu Ting
On January 9, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 9, Chow Yiu-ting increased her OTC share holdings of $Pilot Pharmaceutical Biotechnology (00399.HK) by $50 million at an average price of HK$0.21 per share, worth about HK$10.5 million on January 8. After the increase in holdings, Chow Yiu-ting's latest shareholding was 429 million shares, and the good position ratio increased from 22.70% to 25.69%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies.
Pilot Pharmaceutical Biotechnology (00399) issued approximately 99 million shares due to the conversion of convertible bonds
Pilot Pharmaceutical Biotechnology (00399) issued an announcement. The company issued on December 31, 2014 in accordance with the exercise...
Pilot Pharmaceutical Biotechnology (00399.HK) received an additional 50 million shares of common stock worth approximately HK$10.95 million from Chow Yiu Ting
On January 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on January 5, Chow Yiu-ting increased her OTC share holdings of $Pilot Pharmaceutical Biotechnology (00399.HK) by $50 million at an average price of HK$0.219 per share on January 2, worth about HK$10.95 million. After the increase in holdings, Chow Yiu-ting's latest shareholding was 379 million shares, and the good position ratio increased from 20.94% to 24.13%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies
No Data